17th International Workshop on Pediatrics & HIV 2025

Slideset

HIV

Opening Words - Lynne Mofenson

Slideset

HIV

Global Update on the HIV Epidemic in Infants, Children, Adolescents, and Women - Anna Yakusik

Slideset

HIV

Rwanda Response to Maternal and Pediatric HIV - Gisele Mujawamariya

Slideset

HIV

Abstract #1 Gestational Exposure to an Efavirenz-Containing Compared to a Dolutegravir-Containing Antiretroviral Regimen Is Associated with Lower Anthropometrics at 18 Months of Life among Children HIV-Exposed Uninfected in Botswana - Gosego Masasa

Slideset

HIV

Abstract #2 Infant Safety Following Exposure to Maternal TDF/FTC for HIV Prevention in Utero and Through Breast Milk: IMPAACT 2009 - Elizea Horne

Slideset

HIV

Abstract #3 The Impact of Daily Oral PrEP on Maternal Bone Mineral Density During Pregnancy and Postpartum: IMPAACT 2009 - Elizea Horne

Slideset

HIV

Abstract #4 Impact of Maternal HIV Status on Maternal and Child Peripheral Blood Immune Markers and Associations with Neurometabolite Profiles at Age 6–7 Years: A South African Birth Cohort Study - Cesc Bertran-Cobo

Slideset

HIV

Abstract #5 Validation of a Ministry of Health (MoH) HIV Risk Screening Tool for Breastfeeding Women (BFW) in Northern and Central Mozambique (2022 to 2024) - Marilena Urso

Slideset

HIV

Potential Models for Infant Antiretroviral Prophylaxis to Prevent Perinatal/Postnatal Transmission - Theodore Ruel

Slideset

HIV

What Do We Know About Choice of Antiretrovirals for Infant Prophylaxis to Prevent Transmission? - Adrie Bekker

Slideset

HIV

The Clinical Consequences of Premature Aging in Youth with Perinatal HIV Infection - Rashida Ferrand

Slideset

HIV

Youth Panel: New Platforms, New Possibilities - Supporting Adolescents Living with HIV in a Digital World - Ravel Gatoto

Slideset

HIV

Abstract #6 Did HIV-1 Incidence Decline During the DREAMS Program? Lack of Progress for Adolescent Girls and Young Women - Nora Rosenberg

Slideset

HIV

Abstract #7 Ugandan Teenage Females with PHIV on DTG Have a Distinct Phenotype Concerning for Future Cardiometabolic Risk - Sahera Dirajlal-Fargo

Slideset

HIV

Abstract #9 Mental Health Challenges and Substance Use Associated with Poor Viral Suppression and Transition Readiness among Adolescents with HIV Transitioning to Adult Care - Brian Zanoni

Slideset

HIV

Abstract #10 Outcomes of Children and Young Adolescents Receiving ART Under Family-Based DSD Model at Largest Public ART Clinic in Lilongwe, Malawi - Petros P.M. Tembo

Slideset

HIV

Gene Therapy and Remission - Mauricio Martins

Slideset

HIV

Abstract #11 Predictors of Treatment Failure in Children Living with HIV Starting First-Line Antiretroviral Therapy in the ODYSSEY Trial - James Wyncoll

Slideset

HIV

Abstract #12 Factors Associated with HIV-1 DNA Dynamics in Early Treated Children with Perinatal HIV - Alfredo Tagarro Garcia

Slideset

HIV

Abstract #13 Efficacy and Safety of Emtricitabine/Tenofovir Alafenamide (F/TAF) Plus Cobicistat-Boosted Protease Inhibitors in Children with HIV-1 Aged 2-<12 Years and Weighing 14-<40 kg: Week 48 Outcomes - Hilda Angela Mujuru

Slideset

HIV

Abstract #14 Effectiveness and Safety of Dolutegravir (DTG) in Infants and Children Aged Under 12-Years at Start of DTG in Europe and Thailand - Intira Jeannie Collins

Slideset

HIV

Abstract #15 Efficacy of Second-Line Dolutegravir- versus Boosted Protease Inhibitor-Based ART in Children and Adolescents Living with HIV at 96 and 144 Weeks: Pooled Analysis of the ODYSSEY and CHAPAS-4 Trials - Pauline Amuge

Slideset

HIV

Debate: All Young Adults with Perinatal HIV Should Receive a Statin to Reduce the Risk of Cardiovascular-Related Morbidity and Mortality - Con Standpoint - Victor Musiime

Slideset

HIV

Tuberculosis

Abstract #17 Effect of TB Preventive Treatment on TB Incidence and Non-TB-Related Mortality among Children and Adolescents Living with HIV Initiated on Antiretroviral Therapy in Cameroon, 2020-2022 - Boris Kevin Tchounga

Slideset

HIV

Abstract #18 Infectious Morbidity among Children HIV-Exposed, Uninfected in South Africa: Elevated Risk in Infancy But Not Thereafter - Kim Anderson

Slideset

HIV

Abstract #19 Growth Trajectories Before and After Switching to Dolutegravir in Children Living with HIV in the ODYSSEY Trial - Man K. Chan

Slideset

HIV

HPV Vaccine and Cervical Cancer Prevention in Africa - Nelly Mugo

Slideset

HIV

Abstract #20 Telomere Length and Neurodevelopmental Outcomes among Children Exposed and Not Exposed to HIV in Kenya - Jillian Neary

Slideset

HIV

Abstract #21 Switching Off Dolutegravir in Pregnancy During the Safety Signal Period: A Multi-Cohort European Study - Georgina Fernandes

Slideset

HIV

Abstract #22 Causes of Death among Sub-Saharan African Infants Living with HIV and Hospitalised with Severe Pneumonia Using Minimally Invasive Autopsies in the EMPIRICAL Trial - Maria de la Cinta Moraleda Redecilla

Slideset

HIV

Abstract #23 Association Between Reservoir Size and Markers of Cardiovascular Inflammation in Perinatally Infected Children Living with HIV - Fatima Kakkar

Slideset

HIV

Clinical Case #1 - Vincent Ganu

Slideset

HIV

Clinical Case #2 - Kagiso Mochankana

Slideset

HIV

17th International Workshop on Pediatrics & HIV 2025

Opening Words - Lynne Mofenson

Global Update on the HIV Epidemic in Infants, Children, Adolescents, and Women - Anna Yakusik

Rwanda Response to Maternal and Pediatric HIV - Gisele Mujawamariya

Abstract #1 Gestational Exposure to an Efavirenz-Containing Compared to a Dolutegravir-Containing Antiretroviral Regimen Is Associated with Lower Anthropometrics at 18 Months of Life among Children HIV-Exposed Uninfected in Botswana - Gosego Masasa

Abstract #2 Infant Safety Following Exposure to Maternal TDF/FTC for HIV Prevention in Utero and Through Breast Milk: IMPAACT 2009 - Elizea Horne

Abstract #3 The Impact of Daily Oral PrEP on Maternal Bone Mineral Density During Pregnancy and Postpartum: IMPAACT 2009 - Elizea Horne

Abstract #4 Impact of Maternal HIV Status on Maternal and Child Peripheral Blood Immune Markers and Associations with Neurometabolite Profiles at Age 6–7 Years: A South African Birth Cohort Study - Cesc Bertran-Cobo

Abstract #5 Validation of a Ministry of Health (MoH) HIV Risk Screening Tool for Breastfeeding Women (BFW) in Northern and Central Mozambique (2022 to 2024) - Marilena Urso

Potential Models for Infant Antiretroviral Prophylaxis to Prevent Perinatal/Postnatal Transmission - Theodore Ruel

What Do We Know About Choice of Antiretrovirals for Infant Prophylaxis to Prevent Transmission? - Adrie Bekker

The Clinical Consequences of Premature Aging in Youth with Perinatal HIV Infection - Rashida Ferrand

Youth Panel: New Platforms, New Possibilities - Supporting Adolescents Living with HIV in a Digital World - Ravel Gatoto

Abstract #6 Did HIV-1 Incidence Decline During the DREAMS Program? Lack of Progress for Adolescent Girls and Young Women - Nora Rosenberg

Abstract #7 Ugandan Teenage Females with PHIV on DTG Have a Distinct Phenotype Concerning for Future Cardiometabolic Risk - Sahera Dirajlal-Fargo

Abstract #9 Mental Health Challenges and Substance Use Associated with Poor Viral Suppression and Transition Readiness among Adolescents with HIV Transitioning to Adult Care - Brian Zanoni

Abstract #10 Outcomes of Children and Young Adolescents Receiving ART Under Family-Based DSD Model at Largest Public ART Clinic in Lilongwe, Malawi - Petros P.M. Tembo

Gene Therapy and Remission - Mauricio Martins

Abstract #11 Predictors of Treatment Failure in Children Living with HIV Starting First-Line Antiretroviral Therapy in the ODYSSEY Trial - James Wyncoll

Abstract #12 Factors Associated with HIV-1 DNA Dynamics in Early Treated Children with Perinatal HIV - Alfredo Tagarro Garcia

Abstract #13 Efficacy and Safety of Emtricitabine/Tenofovir Alafenamide (F/TAF) Plus Cobicistat-Boosted Protease Inhibitors in Children with HIV-1 Aged 2-<12 Years and Weighing 14-<40 kg: Week 48 Outcomes - Hilda Angela Mujuru

Abstract #14 Effectiveness and Safety of Dolutegravir (DTG) in Infants and Children Aged Under 12-Years at Start of DTG in Europe and Thailand - Intira Jeannie Collins

Abstract #15 Efficacy of Second-Line Dolutegravir- versus Boosted Protease Inhibitor-Based ART in Children and Adolescents Living with HIV at 96 and 144 Weeks: Pooled Analysis of the ODYSSEY and CHAPAS-4 Trials - Pauline Amuge

Debate: All Young Adults with Perinatal HIV Should Receive a Statin to Reduce the Risk of Cardiovascular-Related Morbidity and Mortality - Con Standpoint - Victor Musiime

Abstract #17 Effect of TB Preventive Treatment on TB Incidence and Non-TB-Related Mortality among Children and Adolescents Living with HIV Initiated on Antiretroviral Therapy in Cameroon, 2020-2022 - Boris Kevin Tchounga

Abstract #18 Infectious Morbidity among Children HIV-Exposed, Uninfected in South Africa: Elevated Risk in Infancy But Not Thereafter - Kim Anderson

Abstract #19 Growth Trajectories Before and After Switching to Dolutegravir in Children Living with HIV in the ODYSSEY Trial - Man K. Chan

HPV Vaccine and Cervical Cancer Prevention in Africa - Nelly Mugo

Abstract #20 Telomere Length and Neurodevelopmental Outcomes among Children Exposed and Not Exposed to HIV in Kenya - Jillian Neary

Abstract #21 Switching Off Dolutegravir in Pregnancy During the Safety Signal Period: A Multi-Cohort European Study - Georgina Fernandes

Abstract #22 Causes of Death among Sub-Saharan African Infants Living with HIV and Hospitalised with Severe Pneumonia Using Minimally Invasive Autopsies in the EMPIRICAL Trial - Maria de la Cinta Moraleda Redecilla

Abstract #23 Association Between Reservoir Size and Markers of Cardiovascular Inflammation in Perinatally Infected Children Living with HIV - Fatima Kakkar

Clinical Case #1 - Vincent Ganu

Clinical Case #2 - Kagiso Mochankana

The Science of Premature Aging in Youth with Perinatal HIV Infection - Anita de Rossi